Skip to NavigationSkip to content

AZ's Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer

Published on 30/09/19 at 11:16am

AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new data on Tagrisso (osimertinib) in the first-line treatment of locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Tagrisso was shown to present a “statistically significant and clinically meaningful improvement” in overall survival, extending life by a median of 38.6 months compared to 31.8 months with previous standards of care gefitinib and erlotinib.

After three years of treatment, 28% of Tagrisso patients remained on the first-line study treatment versus just 9% in the study’s comparator arm. Additionally, Tagrisso was shown to reduce the risk of central nervous system disease progression by 52% and extend the length of time patients with CNS metastases lived without CNS disease progression or death.

According to AZ, the drug is the only first-line therapy “to deliver a median overall survival of more than three years” in this indication.

 “Tagrisso has set a new benchmark in EGFR-mutated non-small cell lung cancer by demonstrating a median overall survival of more than three years,” commented José Baselga, Executive Vice President, Oncology R&D.  “We have not before seen survival benefits of this magnitude in any global Phase 3 trial with any such therapy. The ground-breaking data reaffirm the benefit of using Tagrisso first and further support its use as the 1st-line standard of care in this setting.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches